Skip to main content

Sickle Cell Disease Treatment Market Size to Surpass USD 9.84 Billion by 2030, exhibiting a CAGR of 20.1%

As per the report by Fortune Business Insights, the global Sickle Cell Disease Treatment Market size is projected to reach USD 9.84 billion in 2030, at a CAGR of 20.1% during the forecast period, 2023-2030

Sickle Cell Disease Treatment Market

Forecast 2023-2030
Forecast 2023-2030

Pune, India, Oct. 16, 2023 (GLOBE NEWSWIRE) — Global Sickle Cell Disease Treatment Market Size was valued at USD 2.25 billion in 2022 and is projected to USD 9.84 billion by 2030 exhibiting a CAGR of 20.1% during the forecast period. Increasing Collaborations and Strong Government Support to Favor Market Progress in US, Introduction of New Treatment Solutions to Boost Market Growth.

The increasing prevalence of Sickle Cell Disease (SCD) is driving market growth. Growing awareness about SCD and increasing focus on effective drug launches are estimated to propel market progress

This information is provided by Fortune Business Insights™ in its research report titled Sickle Cell Disease Treatment Market, 2023-2030.


Key Industry Development-

  • June 2023: Novartis AG partnered with American Society of Hematology (ASH) to provide six African nations with technology for the diagnosis of sickle cell disease in children.

Request a Sample PDF – https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/sickle-cell-disease-treatment-market-101009


Key Takeaways –

  • Sickle Cell Disease Treatment Market size in U.S. was USD 1.44 billion in 2022.
  • Rising disease prevalence and severity drive demand for effective treatments.
  • Advent of Novel Treatment Solutions to Contribute to Market Growth.
  • The pharmacotherapy segment is expected to hold a major market share during the projected period.


Discover the Leading Players Featured in the Report-

  • Bristol-Myers Squibb Company (U.S.)
  • Addmedica (France)
  • Novartis AG (Switzerland)
  • Global Blood Therapeutics, Inc. (Pfizer Inc.) (U.S.)
  • Emmaus Medical, Inc. (U.S.)
  • bluebird bio Inc. (U.S.)
  • Agios Pharmaceuticals, Inc. (U.S.)


Report Scope & Segmentation:

Report Coverage Details
Forecast Period 2023 to 2030
Forecast Period 2023 to 2030 CAGR 20.1%
2030 Value Projection USD 9.84 Billion
Base Year 2022
Sickle Cell Disease Treatment Market Size in 2022 USD 2.25 Billion
Historical Data for 2019 to 2021
No. of Pages 103
Segments covered Treatment Modality, End User and Geography


Browse Complete Report Details- https://www.fortunebusinessinsights.com/industry-reports/sickle-cell-disease-treatment-market-101009


Drivers & Restraints:

Introduction of New Treatment Solutions to Boost Market Growth

In the past, bone marrow transplants and blood transfusions were the only treatments for sickle cell disease. The increasing SCD prevalence and growing awareness about the disease pushed market participants to develop novel solutions. Increasing preference for effective treatment solutions for sickle cell diseases is expected to boost market expansion. Leading companies are concentrating on introducing new products for sickle cell disease treatment.

However, a lack of awareness about SCD among the population in emerging economies is impeding market growth.


Regional Insights:

Increasing Collaborations and Strong Government Support to Favor Market Progress in the U.S.

The U.S. dominated the global market revenue. Market growth in the country is attributed to a rise in collaborations to advance disease treatment, promising pipeline candidates, and favorable government support. Better access to SCD treatment in the country is contributing to market expansion in the U.S.

Europe held a significant market share. Market growth in the region is driven by supportive reimbursement policies. In Europe, rising sickle cell disorders are likely to favor market expansion. Furthermore, the surging focus on increasing their product offerings by key players in the region is expected to favor market expansion.


Segmentation

Blood Transfusion Segment Dominated the Market due to Stroke Management Benefits

By treatment modality, the market is classified into bone marrow transplant, blood transfusion, and pharmacotherapy.

The blood transfusion segment led the global sickle cell disease treatment market share. Strokes are one of the serious symptoms of SCD. Blood transfusion is the most efficient treatment solution to manage strokes. The increasing need for blood transfusion treatment due to the rising of episodes of strokes among SCD patients is boosting segment growth.

Hospitals Segment Led the Market owing to Increasing Prevalence of In-patient Visits

Based on end-user, the market is divided into hospitals, specialty clinics, and others.

Hospitals registered a significant market share. The segment growth is driven by a rise in the prevalence of in-patient visits for sickle cell disease treatment and the rising incidence of SCD.


Major Table of Contents:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
    • Market Trends
  • Key Insights
    • Prevalence of Sickle Cell Disease, For Key Countries/ Regions, 2023
    • Overview – Branded Drugs (Marketed)
    • Pipeline Analysis, Key Players
    • New Product Launches
    • Key Industry Developments (Mergers, Acquisitions, Partnership; etc.)
    • Impact of COVID-19 on the Market
  • Global Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Treatment Modality
      •  Bone Marrow Transplant
      •  Blood Transfusion
      •  Pharmacotherapy
        •  Hydroxyurea
        •  Branded Products
          •  Endari
          • Adakveo
          • Oxbryta
          • PYRUKYND (Mitapivat)
          • Zynteglo
          • CTX001
          • Inclacumab
          • Vamifeport (VIT-2763)
          • ALXN1820
          • MGTA-145
          • FT-4202
          • GBT021601
    • Market Analysis, Insights and Forecast – By End-user
      •  Hospitals
      •  Specialty Clinics
      •  Others
    • Market Analysis, Insights and Forecast – By Country/Region
      •  U.S.
      •  Europe
      •  Rest of the World
  • U.S. Sickle Cell Disease Treatment Market Analysis, Insights and Forecast, 2019-2030
    • Market Analysis, Insights and Forecast – By Treatment Modality
      •  Bone Marrow Transplant
      •  Blood Transfusion
      •  Pharmacotherapy
        •  Hydroxyurea
        •  Branded Products
          •  Endari
          • Adakveo
          • Oxbryta
          • PYRUKYND (Mitapivat)
          • Zynteglo
          • CTX001
          • Inclacumab
          • Vamifeport (VIT-2763)
          • ALXN1820
          • MGTA-145
          • FT-4202
          • GBT021601
    • Market Analysis, Insights and Forecast – By End-user
      •  Hospitals
      •  Specialty Clinics
      •  Others

Quick Buy – Sickle Cell Disease Treatment Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101009


Competitive Landscape:

Major Companies Deploy Partnerships to Enhance their Product Offerings

Novartis AG accounted for a considerable share of the market. The company is emphasizing partnerships with many government organizations. This enables the company to accomplish patient needs. The company gained a prominent position in the market due to its constant focus on increasing product availability.

In June 2020, with the signing of two new memoranda of understanding with the Ministries of Health of Uganda and Tanzania, Novartis AG confirmed the expansion of the Africa Sickle Cell Disease program to East Africa. The program’s objective is to enhance and extend the lives of SCD patients in sub-Saharan Africa.


FAQs

How big is the Sickle Cell Disease Treatment Market?

Sickle Cell Disease Treatment Market size was USD 2.25 billion in 2022. It is expected to reach USD 9.84 billion in 2030.

How fast is the Sickle Cell Disease Treatment Market growing?

The Sickle Cell Disease Treatment Market will exhibit a CAGR of 20.1% during the forecast period, 2023-2030.

Related Reports:

Blood Transfusion Diagnostics Market Size, Share, Revenue Forecast and Opportunities

Allogeneic Stem Cells Market Overview, Industry Share and Forecast

Iron Deficiency Anemia Therapy Market Analysis, Global Size and Industry Share Forecast


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Attachment

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.